American politician and university administrator
Clinical and reporting threads have converged this week: Insilico Medicine has published midstage data showing its experimental drug rentosertib changed blood‑protein patterns that aging clocks read as roughly three to four years younger in treated patients, while other outlets have highlighted emerging health threats and new research on kidney disease, brain-tumor diets and cardiovascular warning signs.
The FDA has approved daraxonrasib (Rasonque), a once-daily pill from Revolution Medicines, for adults with metastatic pancreatic cancer who have received prior therapy or cannot take combination chemotherapy. A 500‑patient trial has shown median survival of 13.2 months versus 6.7 months for chemotherapy; a 30‑day supply will cost about $39,800 and expanded access has already treated thousands.